Latest Breaking News On - Company us phase - Page 1 : comparemela.com

Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort

MOJAVE – US Phase 1/2a study of DSR 2.0 for treatment of heart failure

United statesCian crosbieCompany or sequanaCompany premarket approvalCompany us phaseSequana medicalEuronext brusselsChief medical officerChief executive officerData safety monitoring boardSeattle heart failurePremarket approvalNorth american

Sequana Medical announces three month follow-up data from

Sequana Medical announces three month follow-up data from
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesCian crosbieCompany premarket approvalCompany or sequanamedicalCompany us phaseSequana medicalEuronext brusselsChief medical officerChief executive officerData safety monitoring boardSeattle heart failurePremarket approvalNorth american

Sequana Medical NV: Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy

Sequana Medical NV: Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesDennis riedlCian crosbieCompany us phaseCompany premarket approvalCompany or sequanamedicalEuronext brusselsChief medical officerSequana medicalChief executive officerData safety monitoring boardSeattle heart failurePremarket approvalNorth american

Moleculin Announces Completion of Enrollment in U S Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including.

United statesJenene thomasWalter klempExchange commissionEastern cooperative oncology groupPrnewswire moleculin biotech incSecurities exchangeCompany us phaseConnective tissue oncology society annual meetingDrug administrationMoleculin biotech incFast track statusOrphan drug designationChief executive officerConnective tissue oncology societyAnnual meeting

Palisade Bio (PALI) Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions Did Not Achieve Primary Endpoint

Palisade Bio (PALI) Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions Did Not Achieve Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Company us phasePalisade bioChief executive officer